-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx publishes Nu.Q NETs platform update presentation on sepsis biomarker data

PUBT·07/30/2026 12:17:25
Listen to the news
VolitionRx publishes Nu.Q NETs platform update presentation on sepsis biomarker data
  • Volition published a presentation updating clinical and scientific evidence for its Nu.Q NETs assay, positioning Nu.Q H3.1 for sepsis management.
  • Presentation: https://volition.com/wp-content/uploads/2026/07/NETs-summary-slide-July-26-1.pdf
  • Update cites consistent international findings that H3.1 nucleosomes distinguish sepsis from non-infectious inflammation, correlate with severity, support prognosis.
  • Presentation states H3.1 adds information beyond standard organ failure scores such as APACHE II and SOFA.
  • Commercial update flags discussions with large diagnostics groups; total addressable market estimated at about $3.8 billion annually.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607300817PR_NEWS_USPR_____LN14796) on July 30, 2026, and is solely responsible for the information contained therein.